vs
汉瑞祥（HSIC）与Leidos（LDOS）财务数据对比。点击上方公司名可切换其他公司
Leidos的季度营收约是汉瑞祥的1.3倍（$4.4B vs $3.4B），Leidos净利率更高（7.6% vs 2.9%，领先4.7%），汉瑞祥同比增速更快（7.7% vs 3.7%），过去两年汉瑞祥的营收复合增速更高（4.1% vs 3.5%）
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
Leidos Holdings, Inc.是总部位于美国弗吉尼亚州雷斯顿的企业，业务覆盖国防、航空、信息技术、生物医学研究领域，提供科研、工程、系统集成及技术服务。其前身为科学应用国际公司（SAIC），2016年8月与洛克希德·马丁旗下IT业务板块合并，成为国防行业规模最大的IT服务提供商。
HSIC vs LDOS — 直观对比
营收规模更大
LDOS
是对方的1.3倍
$3.4B
营收增速更快
HSIC
高出4.1%
3.7%
净利率更高
LDOS
高出4.7%
2.9%
两年增速更快
HSIC
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q1 FY2027
| 指标 | | |
|---|---|---|
| 营收 | $3.4B | $4.4B |
| 净利润 | $101.0M | $335.0M |
| 毛利率 | 30.9% | 17.3% |
| 营业利润率 | 4.7% | 11.5% |
| 净利率 | 2.9% | 7.6% |
| 营收同比 | 7.7% | 3.7% |
| 净利润同比 | 7.4% | -8.2% |
| 每股收益（稀释后） | $0.85 | $2.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSICLDOS
| Q1 26 | — | $4.2B | ||
| Q4 25 | $3.4B | $4.4B | ||
| Q3 25 | $3.3B | $4.2B | ||
| Q2 25 | $3.2B | $4.2B | ||
| Q1 25 | $3.2B | $4.3B | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | $3.2B | $4.2B | ||
| Q2 24 | $3.1B | $4.1B |
净利润HSICLDOS
| Q1 26 | — | $327.0M | ||
| Q4 25 | $101.0M | $367.0M | ||
| Q3 25 | $101.0M | $391.0M | ||
| Q2 25 | $86.0M | $363.0M | ||
| Q1 25 | $110.0M | $284.0M | ||
| Q4 24 | $94.0M | — | ||
| Q3 24 | $99.0M | $364.0M | ||
| Q2 24 | $104.0M | $322.0M |
毛利率HSICLDOS
| Q1 26 | — | 17.4% | ||
| Q4 25 | 30.9% | 18.0% | ||
| Q3 25 | 30.7% | 18.0% | ||
| Q2 25 | 31.4% | 17.5% | ||
| Q1 25 | 31.6% | 15.6% | ||
| Q4 24 | 31.1% | — | ||
| Q3 24 | 31.3% | 17.8% | ||
| Q2 24 | 32.5% | 16.6% |
营业利润率HSICLDOS
| Q1 26 | — | 11.3% | ||
| Q4 25 | 4.7% | 12.0% | ||
| Q3 25 | 4.9% | 13.5% | ||
| Q2 25 | 4.7% | 12.5% | ||
| Q1 25 | 5.5% | 9.7% | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 4.9% | 12.4% | ||
| Q2 24 | 5.1% | 11.6% |
净利率HSICLDOS
| Q1 26 | — | 7.8% | ||
| Q4 25 | 2.9% | 8.2% | ||
| Q3 25 | 3.0% | 9.2% | ||
| Q2 25 | 2.7% | 8.6% | ||
| Q1 25 | 3.5% | 6.5% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 3.1% | 8.7% | ||
| Q2 24 | 3.3% | 7.8% |
每股收益（稀释后）HSICLDOS
| Q1 26 | — | $2.54 | ||
| Q4 25 | $0.85 | $2.82 | ||
| Q3 25 | $0.84 | $3.01 | ||
| Q2 25 | $0.70 | $2.77 | ||
| Q1 25 | $0.88 | $2.10 | ||
| Q4 24 | $0.75 | — | ||
| Q3 24 | $0.78 | $2.68 | ||
| Q2 24 | $0.80 | $2.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.0M | $457.0M |
| 总债务越低越好 | $2.3B | $6.0B |
| 股东权益账面价值 | $3.2B | $5.1B |
| 总资产 | $11.2B | $15.4B |
| 负债/权益比越低杠杆越低 | 0.71× | 1.19× |
8季度趋势，按日历期对齐
现金及短期投资HSICLDOS
| Q1 26 | — | $1.1B | ||
| Q4 25 | $156.0M | $974.0M | ||
| Q3 25 | $136.0M | $930.0M | ||
| Q2 25 | $145.0M | $842.0M | ||
| Q1 25 | $127.0M | $943.0M | ||
| Q4 24 | $122.0M | — | ||
| Q3 24 | $126.0M | $1.2B | ||
| Q2 24 | $138.0M | $823.0M |
总债务HSICLDOS
| Q1 26 | — | $4.6B | ||
| Q4 25 | $2.3B | $4.6B | ||
| Q3 25 | $2.2B | $5.0B | ||
| Q2 25 | $2.1B | $5.0B | ||
| Q1 25 | $2.0B | $4.1B | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | $4.1B | ||
| Q2 24 | $1.9B | $4.1B |
股东权益HSICLDOS
| Q1 26 | — | $4.9B | ||
| Q4 25 | $3.2B | $4.9B | ||
| Q3 25 | $3.4B | $4.7B | ||
| Q2 25 | $3.4B | $4.3B | ||
| Q1 25 | $3.3B | $4.4B | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $3.5B | $4.6B | ||
| Q2 24 | $3.5B | $4.5B |
总资产HSICLDOS
| Q1 26 | — | $13.5B | ||
| Q4 25 | $11.2B | $13.5B | ||
| Q3 25 | $11.1B | $13.5B | ||
| Q2 25 | $10.9B | $13.2B | ||
| Q1 25 | $10.5B | $13.1B | ||
| Q4 24 | $10.2B | — | ||
| Q3 24 | $10.6B | $13.3B | ||
| Q2 24 | $10.3B | $12.9B |
负债/权益比HSICLDOS
| Q1 26 | — | 0.94× | ||
| Q4 25 | 0.71× | 0.94× | ||
| Q3 25 | 0.64× | 1.07× | ||
| Q2 25 | 0.61× | 1.18× | ||
| Q1 25 | 0.59× | 0.92× | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.54× | 0.88× | ||
| Q2 24 | 0.54× | 0.92× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $381.0M | $301.0M |
| 自由现金流经营现金流 - 资本支出 | $338.0M | — |
| 自由现金流率自由现金流/营收 | 9.8% | — |
| 资本支出强度资本支出/营收 | 1.3% | — |
| 现金转化率经营现金流/净利润 | 3.77× | 0.90× |
| 过去12个月自由现金流最近4个季度 | $573.0M | — |
8季度趋势，按日历期对齐
经营现金流HSICLDOS
| Q1 26 | — | $495.0M | ||
| Q4 25 | $381.0M | — | ||
| Q3 25 | $174.0M | $711.0M | ||
| Q2 25 | $120.0M | $58.0M | ||
| Q1 25 | $37.0M | $299.0M | ||
| Q4 24 | $204.0M | — | ||
| Q3 24 | $151.0M | $656.0M | ||
| Q2 24 | $296.0M | $374.0M |
自由现金流HSICLDOS
| Q1 26 | — | $452.0M | ||
| Q4 25 | $338.0M | — | ||
| Q3 25 | $141.0M | $680.0M | ||
| Q2 25 | $88.0M | $36.0M | ||
| Q1 25 | $6.0M | $213.0M | ||
| Q4 24 | $168.0M | — | ||
| Q3 24 | $117.0M | $633.0M | ||
| Q2 24 | $259.0M | $351.0M |
自由现金流率HSICLDOS
| Q1 26 | — | 10.8% | ||
| Q4 25 | 9.8% | — | ||
| Q3 25 | 4.2% | 16.1% | ||
| Q2 25 | 2.7% | 0.9% | ||
| Q1 25 | 0.2% | 4.9% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 3.7% | 15.2% | ||
| Q2 24 | 8.3% | 8.5% |
资本支出强度HSICLDOS
| Q1 26 | — | 1.0% | ||
| Q4 25 | 1.3% | — | ||
| Q3 25 | 1.0% | 0.7% | ||
| Q2 25 | 1.0% | 0.5% | ||
| Q1 25 | 1.0% | 2.0% | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 1.1% | 0.6% | ||
| Q2 24 | 1.2% | 0.6% |
现金转化率HSICLDOS
| Q1 26 | — | 1.51× | ||
| Q4 25 | 3.77× | — | ||
| Q3 25 | 1.72× | 1.82× | ||
| Q2 25 | 1.40× | 0.16× | ||
| Q1 25 | 0.34× | 1.05× | ||
| Q4 24 | 2.17× | — | ||
| Q3 24 | 1.53× | 1.80× | ||
| Q2 24 | 2.85× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
LDOS
暂无分部数据
